Intermittent endocrine therapy for advanced prostate cancer

Area of Science:

• Oncology
• Urology

Background:

• Advanced prostate cancer often requires long-term treatment.
• Continuous hormone therapy can lead to significant side effects.

Purpose of the Study:

• To evaluate the efficacy of intermittent endocrine therapy in advanced prostate cancer.
• To assess the impact on palliation and patient quality of life.

Main Methods:

• Twenty patients with advanced prostate cancer received intermittent hormone therapy (diethylstilbestrol or flutamide).
• Therapy was administered until clinical response, then withheld until symptom recurrence.
• Treatment was resumed upon relapse.

Main Results:

• Satisfactory palliation was achieved in selected patients.
• Disease progression occurred after therapy interruption, with rapid response upon resumption.
• Nine of ten patients regained sexual activity after treatment cessation.

Conclusions:

• Intermittent endocrine therapy is a viable option for managing advanced prostate cancer.
• This approach can offer effective palliation with potentially improved quality of life.
• Further research may explore optimal scheduling and patient selection criteria.